DSpace at RU >

Browsing by Author Suciu, S.

Full Text	Issue Date	Title	Author(s)
	2011	Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032)	Patel, P.M.; Suciu, S.; Mortier, L.; Kruit, W.H.; Robert, C., et al
	2011	Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group	Lubbert, M.; Suciu, S.; Baila, L.; Ruter, B.H.; Platzbecker, U., et al
	2010	Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial.	Witte, T.J.M. de; Hagemeijer, A.; Suciu, S.; Belhabri, A.; Delforge, M., et al
	2010	Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.	Bouwhuis, M.G.; Suciu, S.; Testori, A.; Kruit, W.H.; Sales, F., et al
	2010	Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group.	Labar, B.; Suciu, S.; Willemze, R.; Muus, P.; Marie, J.P., et al
	2010	Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19).	Amadori, S.; Suciu, S.; Selleslag, D.; Stasi, R.; Alimena, G., et al
	2009	Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.	Mandelli, F.; Vignetti, M.; Suciu, S.; Stasi, R.; Petti, M.C., et al
	2009	Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.	Bouwhuis, M.G.; Suciu, S.; Collette, S.; Aamdal, S.; Kruit, W.H., et al
	2009	Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study).	Fusi, A.; Collette, S.; Busse, A.; Suciu, S.; Rietz, A., et al
	2009	Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.	Bottomley, A.; Coens, C.; Suciu, S.; Santinami, M.; Kruit, W., et al
	2008	Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.	Eggermont, A.M.; Suciu, S.; Santinami, M.; Testori, A.; Kruit, W.H., et al
	2007	Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.	Thomas, X.; Suciu, S.; Rio, B.; Leone, G.; Broccia, G., et al
	2007	Which myelodysplastic syndromes patients are candidates for transplantation?	Witte, T.J.M. de; Witte, T.J.M. de; Biezen, A. van; Brand, R.; Suciu, S., et al
	2007	Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.	Schmidt, H.; Suciu, S.; Punt, C.J.A.; Gore, M.; Kruit, W., et al
	2007	Autologous stem cell transplantation in myelodysplastic syndromes.	Witte, T.J.M. de; Suciu, S.; Brand, R.; Muus, P.; Kroger, N.
	2007	Stem cell transplantation in ALL: a donor versus no donor comparison in the EORTC ALL-4 study.	Labar, B.; Suciu, S.; Muus, P.; Willemze, R.; Marie, J.P., et al
	2006	Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.	Punt, C.J.A.; Suciu, S.; Gore, M.; Koller, J.; Kruit, W., et al
	2006	Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial.	Jehn, U.; Suciu, S.; Thomas, X.; Lefrere, F.; Muus, P., et al
	2005	Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group.	Zwierzina, H.; Suciu, S.; Loeffler-Ragg, J.; Neuwirtova, R.; Fenaux, P., et al
	2005	Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.	Eggermont, A.M.M.; Suciu, S.; MacKie, R.; Ruka, W.; Testori, A., et al
	2005	Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups.	Amadori, S.; Suciu, S.; Stasi, R.; Willemze, R.; Mandelli, F., et al
	2005	Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study.	Amadori, S.; Suciu, S.; Jehn, U.; Stasi, R.; Thomas, X., et al
	2005	Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.	Keilholz, U.; Punt, C.J.A.; Gore, M.; Kruit, W.; Patel, P., et al
	2004	Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis.	Kleeberg, U.R.; Suciu, S.; Bröcker, E.B.; Ruiter, D.J.; Chartier, C., et al
	2004	Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma for patients <or=50 years old in first complete remission: results of the EORTC ALL-3 trial.	Labar, B.; Suciu, S.; Zittoun, R.; Muus, P.; Marie, J.P., et al
	2004	Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups.	Amadori, S.; Suciu, S.; Willemze, R.; Mandelli, F.; Selleslag, D., et al
	2004	Autologous versus allogeneic stem cell transplantation in acute myeloid leukemia.	Willemze, R.; Suciu, S.; Mandelli, F.; Witte, T.J.M. de; Amador, S.
	1997	Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the research and treatment of cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON)	Lowenberg, B.; Suciu, S.; Archimbaud, E.; Ossenkoppele, G.J.; Verhoef, G.E.G., et al
	1997	A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893)	Willemze, R.; Suciu, S.; Archimbaud, E.; Muus, P.; Stryckmans, P., et al
	1997	Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial	Zittoun, R.; Suciu, S.; Watson, M.A.; Solbu, G.; Muus, P., et al
	1996	Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (06901) of the EORTC Leukemia Cooperative Group	Witte, T.J.M. de; Suciu, S.; Selleslag, D.; Labar, B.; Roozendaal, K.J., et al
	1996	High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia: results of protocol ALL VI from the Dutch Childhood Leukemia Study Group.	Veerman, A.J.P.; Hählen, K.; Kamps, W.A.; Leeuwen, E.F. van; Vaan, G.A.M. de, et al
	1996	Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial	Keating, S.; Suciu, S.; Witte, T.J.M. de; Mandelli, F.; Willemze, R., et al
	1996	Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for research and treatment of cancer leukemia cooperative group	Zittoun, R.; Suciu, S.; Mandelli, F.; Witte, T.J.M. de; Thaler, J., et al
	1995	Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia	Zittoun, R.; Mandelli, F.; Willemze, R.; Witte, T. de; Labar, B., et al
	1995	Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration : a pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG)	Witte, T.J.M. de; Suciu, S.; Peetermans, M.; Fenaux, P.; Strijckmans, P., et al